All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is new in CAR T-cell therapy for ALL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new in CAR T-cell therapy for ALL?

What is new in CAR T-cell therapy for ALL?

Nagler discusses the current experience of chimeric antigen receptor (CAR) T-cell therapy in treating patients with acute lymphoblastic leukemia (ALL). He talks about factors of prognostic value, and the need for allogeneic stem cell transplantation.

 

Share: